Literature DB >> 11490938

[Morphological findings and medical insurance aspects in 371 exhumations].

U Stachetzki1, M A Verhoff, K Ulm, K M Müller.   

Abstract

OBJECTIVES: The morphological findings in organ systems following exhumation, form the basis for answering a number of medical insurance issues. The aim of this study was to analyse the development of the number of exhumations performed and the medical insurance relevance over a 31-year-period.
METHODS: A total of 371 exhumations, performed between 1967-1998 at the Institute of Pathology, Occupational Associations Hospital, Bochum, for medical insurance reasons were evaluated.
RESULTS: The average number of days after burial was 74, ranging from 9 to 47.8. For the first third of the period investigated, the proportion of exhumations was 3.5% of all autopsy cases, for the second third this fell to about 0.4% and rose to 1.5% for the last third. In the first two-thirds, the main reasons for the exhumations were related to the grading and effects of pneumoconioses in connection with the cause of death. In the last third, asbestos-associated diseases were mainly involved. In 99.2% of all cases, the autopsy results revealed important evidence for clarification of the medical insurance issues. The current catalogue of expectations listing the pathomorphological findings which can be expected after certain periods of internment, could be extended by our own results.

Entities:  

Mesh:

Year:  2001        PMID: 11490938     DOI: 10.1007/s002920100460

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  2 in total

1.  [Obligation to report occupational diseases. Importance of external post-mortem examinations before cremation].

Authors:  M A Verhoff; M Risse; J-U Alles; K-M Müller; U Stachetzki
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

2.  Analysis of 155 consecutive forensic exhumations with emphasis on undetected homicides.

Authors:  B Karger; G Lorin de la Grandmaison; T Bajanowski; B Brinkmann
Journal:  Int J Legal Med       Date:  2004-02-20       Impact factor: 2.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.